Greenphire introduces new budget tool to streamline clinical trails
Category: #health  By Pankaj Singh  Date: 2020-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Greenphire introduces new budget tool to streamline clinical trails

Greenphire Inc, one of the world’s leading companies in financial lifecycle management for clinical trials, has reportedly launched a new budget development solution named EnvisiX to address the budgeting challenges experienced by CROs and global sponsors during study start-up. The company has developed a new tool to streamline clinical trials for CROs and sponsors and reduces guesswork during the budgeting phase to offer a smarter, more efficient workflow.

According to sources, EnvisiX effortlessly integrates with the company’s industry-leading site payment solution eClinicalGPS. From budget creation, negotiation, execution, management, to tracking of global investigator grants, the integration would help companies to facilitate efficiency and simplicity throughout a clinical trial.

Moreover, the tool gives access to the contemporary and robust investigator grant payment data in the industry. It also helps sponsors and CROs to streamline the negotiation workflow for enhanced transparency, collaboration, transparency, and management of adjustments, rates, adjudications, approvals, and more.

Speaking on which, Jim Murphy, CEO of Greenphire said that the company is committed to engineering workflow and data solutions that renovate business processes, decreasing the administrative burden and enhancing process effectiveness at every step of the clinical study.

Mr. Murphy added that EnvisiX will help stakeholders to gain visibility and control over the fragmented and manual budget build and negation workflows, ensuring enhanced accuracy and speed along the way.

For years, CROs and sponsors were not satisfied with their study start-up process and then the company built EnvisiX to solve issues related to existing workflows and solutions available in the market today, said, Kyle Cunningham, Chief Product Officer (CPO) at Greenphire.

Mr. Cunningham added that EnvisiX provides clients with user-friendly and streamlined experience for building a budget and eventually to enable defensibility, maximized confidence, and end-to-end efficiency through direct integration and a feedback loop with the company’s leading site payment solution eClinicalGPS.

Source Credit - https://www.wfmz.com/news/pr_newswire/pr_newswire_pennsylvania/greenphire-launches-new-clinical-trial-budget-build-and-negotiation-solution-envisix/article_b7d93a66-8775-529e-82e9-94d065ae4433.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...